Advertisement
Advertisement

ANIK

ANIK logo

Anika Therapeutics Inc

21.42
USD
Sponsored
+1.26
+6.25%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

21.47

+0.05
+0.23%

Anika Therapeutics Inc Profile

About

Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Info & Links

CEO

Stephen Griffin

Headquarters

32 WIGGINS AVENUE
BEDFORD, MA 01730, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.anika.com

Auditor

Deloitte & Touche LLP

Share holders

96

Employees

235

Anika Therapeutics Inc Statistics

Valuation Measures

Market Capitalization2

287.33M

Enterprise Value

248.92M

Enterprise Value/EBITDA(ttm)

486.17

Price to Earnings Ratio(ttm)

1.07K

Price to Sales(ttm)

2.38

Price to Book(mrq)

2.09

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

61.99%

Operating Margin(ttm)

0.23%

Profit Margin(ttm)

-3.59%

Return on Equity(ttm)

0.20%

Return on Invested Capital(ttm)

-2.27%

Return on Assets(ttm)

0.15%

Income Statement

Revenue(ttm)

120.65M

Revenue Per Share(ttm)

9.02

Gross Profit(ttm)

75.00M

EBITDA(ttm)3

512.00K

Net Income Available to Common(ttm)

-3.78M

Diluted EPS(ttm)

-0.27

Share Statistics

Beta (5Y Monthly)

0.20

52-Week Change

164.12%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

13.38M

Dividend Yield

0.00%

Float4

11.77M

% Held by Insiders

12.08%

% Held by Institutions

91.53%

Balance Sheet

Total Cash(mrq)

38.41M

Total Cash Per Share(mrq)

2.87

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

4.48%

Quick Ratio(mrq)

3.19%

Book Value Per Share(mrq)

10.26

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.40

Free Cash Flow(ytd)

-8.41M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement